Neuroprotection: Present and future

Therapie

Volumn 62, Issue 6, 2007, Pages 473-476

  Bordet, Régis ^a,d   Lestage, Pierre ^b   Onteniente, Brigitte ^c   Bouhours, Philippe ^e   Marlangue, C Charriaut ^f   Chollet, François ^c   Fouchard, Marie ^g   Goni, Sylvia ^h   Hommel, C Marc ⁱ   Lacomblez, Lucette ^j   Marquet, Thierry ^h   Nieoullon, André ^k   Pruss, Rebecca ^l   Quintin, P ^m   Rascol, Olivier ⁿ   Stanko, Bruno ^j   Vray, Muriel ^o  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^c INSERM   (France)

^d UNIV LILLE   (France)

^e Janssen Cilag   (France)

^f CNRS   (France)

^g Dohme Chibret Centre de Recherche Riom   (France)

^h Lunbeck   (France)

ⁱ GRENOBLE UNIVERSITY HOSPITAL   (France)

^j PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^k Université Pierre et Marie Curie   (France)

^l Trophos SA   (France)

^m Lilly SA   (France)

ⁿ UNIVERSITÉ PAUL SABATIER   (France)

^o INSTITUT PASTEUR   (France)

more..

Author keywords

Clinical trial; Mental health disease; Methodology; Neurodegenerative disease; Neuroprotection; Stroke

Indexed keywords

NEUROPROTECTIVE AGENT;

BRAIN DISEASE; CLINICAL EVALUATION; CLINICAL TRIAL; DISEASE COURSE; HUMAN; MENTAL DISEASE; NERVE CELL NECROSIS; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE;

EID: 48749114426     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie:2007078     Document Type: Article

References (17)

1. Liebeskind DS, Kasner SE. Neuroprotection for ischaemic stroke. An unattainable goal? CNS Drugs 2001; 15: 165-74
2. Green AR. Why do neuroprotective drugs that are so promising in animals fail in the clinic? An industry perspective. Clin Exp Pharmacol Physiol 2002; 29: 1030-4
3. Citron M. Strategies for disease modification in Alzheimer's disease. Nature Rev Neurosci 2004; 5: 677-85
4. Pitkänen A. Clinical trial in neuroprotection. IDrugs 2003; 6: 200-3
5. Vajda FJE. Neuroprotection and neurodegenerative disease. J Clin Neurosci 2002; 9: 4-8
6. Ferriero DM. Protecting neurons. Epilepsia 2005; 46 (suppl 7): 45-51
7. Lieberman JA, Perkins DO, Jarskog LF. Neuroprotection: a therapeutic strategy to prevent deterioration associated with schizophrenia. CNS Spectr 2007; 12 (suppl 4): 1-13
8. Martino G. How the brain repairs itself: new therapeutic strategies in inflammatory and degenerative CNS disorders. Lancet Neurology 2004; 3: 372-8
9. EMEA. Slowing the progression of neurodegenerative diseases: medicinal products clinical development. EMEA/512562/2006
10. Lees KR. Neuroprotection. Br Med Bull 2000; 56: 401-12
11. De Keyser J, Sulter G, Luiten PG. Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing? Trends Neurosci 1999; 22: 535-40
12. Conforti L, Adalbert R, Coleman MP. Neuronal death: where does the end begin? Trends Neurosci 2007; 30: 159-66
13. Gladstone DJ, Black SE, Hakim AM. Toward wisdom from failure. Lessons from neuroprotective stroke trials and new therapeutic directions. Stroke 2002; 33: 2123-36
14. Ikonomidou C, Turski L. Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury. Lancet Neurology 2002; 1: 383-6
15. Fisher M, Albers GW, Donnan GA, et al. Enhancing the development and approval of acute stroke therapies: Stroke Therapy Academic Industry Roundtable. Stroke 2005; 36: 1808-13
16. Borroni B, Premi E, Di Luca M, et al. Combined biomarkers for early Alzheimer disease diagnosis. Curr Med Chem 2007; 14: 1171-8
17. Vellas B, Andrieu S, Sampaio C, Disease-modifying trials in Alzheimer's disease: a European task force consensus. Lancet Neurology 2007; 6: 56-62